Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver metastases resection surgery with or without primary cancer resection. One cycle of treatment will consist of 14 days (2 weeks).

Trial Details

NCT ID
NCT06225843
Phase
PHASE2
Sponsor
Alethia Biotherapeutics
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Sotevtamab
  • FOLFOX
Locations (sample)
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Participants (male or non-pregnant female) must be ≥ 18 years of age on the day of signing the informed consent.
  • Participants with stage IV colon or rectal adenocarcinoma with resectable liver-dominant metastases and candidate to neoadjuvant FOLFOX followed by…
  • Participants may have had resection of their primary colon or rectal adenocarcinoma in the past or will have their primary cancer resected at the s…
  • Participants must not have received prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy and radiotherapy following resection of …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →